Showing results (261-270 of 382) with videos related to
Sort By:
Pageof 39
Leukemia|January 8, 2025
A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agentsRabia Shahswar, Razif Gabdoulline, Katja Krueger, et al.Nature Medicine|July 10, 2010
Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemiaMichael G Kharas, Christopher J Lengner, Fatima Al-Shahrour, et al.Leukemia|April 18, 2024
Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancerChristopher Maximilian Arends, Klara Kopp, Raphael Hablesreiter, et al.Haematologica|January 18, 2015
ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study GroupPeter Paschka, Richard F Schlenk, Verena I Gaidzik, et al.Hemasphere|January 16, 2025
Impact of myelodysplasia-related and additional gene mutations in intensively treated patients with NPM1-mutated AMLSibylle Cocciardi, Maral Saadati, Nina Weiß, et al.European Journal of Cancer (Oxford, England : 1990)|January 23, 2025
Reduced monocytic IL10 expression in PD1 inhibitor-treated patients is a harbinger of severe immune-related adverse eventsStanislav Rosnev, Baldur Sterner, Phillip Schiele, et al.Nature Communications|January 9, 2020
Single-cell analysis based dissection of clonality in myelofibrosisElena Mylonas, Kenichi Yoshida, Mareike Frick, et al.Cell|September 3, 2011
AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemiasStephen M Sykes, Steven W Lane, Lars Bullinger, et al.Genome Medicine|June 20, 2014
Early aberrant DNA methylation events in a mouse model of acute myeloid leukemiaMiriam Sonnet, Rainer Claus, Natalia Becker, et al.Neuro-Oncology Advances|August 11, 2021
A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3Marc-Eric Halatsch, Richard E Kast, Georg Karpel-Massler, et al.Pageof 39